dc.creator | Lorenzo González, Laura | es |
dc.creator | Valdés Delgado, Teresa | es |
dc.creator | Vázquez Morón, Juan María | es |
dc.creator | Castro Laria, Luisa | es |
dc.creator | Leo Carnerero, Eduardo | es |
dc.creator | Maldonado Pérez, María Belén | es |
dc.creator | Sánchez Capilla, Damián | es |
dc.creator | Pallarés Manrique, Héctor | es |
dc.creator | Sáez Díaz, Antonia | es |
dc.creator | Argüelles Arias, Federico | es |
dc.date.accessioned | 2024-04-30T14:04:20Z | |
dc.date.available | 2024-04-30T14:04:20Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Lorenzo González, L., Valdés Delgado, T., Vázquez Morón, J.M., Castro Laria, L., Leo Carnerero, E., Maldonado Pérez, M.B.,...,Argüelles Arias, F. (2022). Ustekinumab in Crohn’s disease: real-world outcomes and predictors of response. Revista Española de Enfermedades Digestivas, 114 (5), 272-279. https://doi.org/10.17235/reed.2020.7352/2020. | |
dc.identifier.issn | 1130-0108 | es |
dc.identifier.uri | https://hdl.handle.net/11441/157360 | |
dc.description.abstract | Background: ustekinumab is a monoclonal antibody that
inhibits interleukins IL-12 and IL-23, and is approved for the
treatment of Crohn’s disease (CD) and, more recently, also
ulcerative colitis (UC). The aim of this study was to evaluate
the effectiveness and safety of ustekinumab, as well as to
identify possible predictive factors of response in a real-life
setting.
Methods: an observational, retrospective, multicenter study
was carried out in 4 hospitals in Andalusia. Adult patients
with a confirmed diagnosis of CD treated with ustekinum ab from 2017 to 2019 were included. Clinical response
was analyzed at 3, 6 and 12 months of treatment. Clinical
disease activity was assessed with the Harvey-Bradshaw
index (HBI) and the Crohn’s Disease Activity Index (CDAI);
biochemical response was assessed with lab parameters
such as CRP and ESR. One-year ustekinumab drug-survival
was analyzed.
Results: a total of 98 patients were analyzed (mean age, 43
years; 52 % were male); 56 % had failed with ≥ 2 previous
biologicals therapies. At 3 months, 69 % of the patients
were in response and 40.8 % in remission. At 6 months,
56 % were in clinical remission. At 12 months, 73.7 % were
in clinical response and 60.5 % in remission. Corticoste roid-free remission was 32.4 %, 44 %, and 47.4 % at 3, 6, and
12 months, respectively. Cumulative survival after one year
of treatment with ustekinumab was 85.3 %. Biochemical
parameters such as CRP and ESR showed a statistically
significant decrease between baseline and control levels at 3, 6, and 12 months. A lower HBI at baseline and female
sex were predictors of corticosteroid-free clinical remission
in a univariate analysis. In the multivariate analysis no vari ables were found as predictors of corticosteroid-free clinical
remission.
Conclusion: ustekinumab therapy is safe and useful, induc ing clinical response in more than 50 % of patients, includ ing patients who failed with other biologica. | es |
dc.format | application/pdf | es |
dc.format.extent | 8 p. | es |
dc.language.iso | eng | es |
dc.publisher | Aran Ediciones S.A. | es |
dc.relation.ispartof | Revista Española de Enfermedades Digestivas, 114 (5), 272-279. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Inflammatory bowel disease | es |
dc.subject | Crohn’s disease | es |
dc.subject | Ustekinumab | es |
dc.title | Ustekinumab in Crohn’s disease: real-world outcomes and predictors of response | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.reed.es/ArticuloFicha.aspx?id=5296&hst=0&idR=108&tp=1 | es |
dc.identifier.doi | 10.17235/reed.2020.7352/2020 | es |
dc.journaltitle | Revista Española de Enfermedades Digestivas | es |
dc.publication.volumen | 114 | es |
dc.publication.issue | 5 | es |
dc.publication.initialPage | 272 | es |
dc.publication.endPage | 279 | es |